The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

Redburn Atlantic initiated coverage of Alnylam with a Buy rating and $353 price target Therapeutic options for patients with transthyretin ...

Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...

AMVUTTRA is an RNAi therapeutic that works ... M.D., Chief Medical Officer of Alnylam. “Data showing beneficial effects on cardiac systolic and diastolic function are novel and indicate the ...

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler ...

Vutrisiran is already approved as Amvuttra to treat rare disease hereditary ATTR amyloidosis, so approval in Stargardt disease would prompt the pricing negotiation mechanism. Alnylam's earlier ...

Last week, the agency signed off on Alnylam’s Amvuttra to treat transthyretin amyloid cardiomyopathy (ATTR-CM) patients. Sanofi originally partnered on the development of both Amvuttra and Qfitlia.

Alnylam Pharmaceuticals ALNY obtained FDA approval for the label expansion of its lead drug, Amvuttra (vutrisiran), for treating the cardiomyopathy of wild-type or hereditary transthyretin ...

It was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Cassava Sciences, Inc ...

Also in March, Alnylam announced FDA approval of vutrisiran (Amvuttra), an RNA interfering small molecule transthyretin stabilizer, for the treatment of transthyretin amyloidosis with cardiomyopathy.

The reason why is because, as I have noted above, other therapies like that of AMVUTTRA from Alnylam Pharmaceuticals [plus others] require life-long chronic treatment. On the other hand ...